PYPD
PolyPid Ltd.
NASDAQ · Healthcare · Biotechnology · IL
$5.60
+2.56%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$5.56
From 52W high−3.11%
Volume48728.00
Market cap$113.75M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataNov 4, 2026
Open
$5.56
From 52W high
−3.11%
Volume
48728.00
Market cap
$113.75M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−3.7x
P/E (TTM)
—
RSI (14)
57.4
MomentumView details →
1D Return
+2.56%
YTD Return
+26.61%
SummaryUpdated Jun 1, 2026
PolyPid Ltd. (NASDAQ:PYPD) is an Israeli late-stage biopharmaceutical company founded in 2008 and headquartered in Petah Tikva, Israel. The company went public in June 2020 and focuses on developing innovative drug delivery solutions using its proprietary polymer-lipid encapsulation matrix (PLEX) platform technology. PolyPid is currently in Phase III clinical trials with its lead product candidate D-PLEX100, designed to prevent surgical site infections, representing a significant unmet medical need in healthcare settings.
Similar companies
Latest newsMore news →
PolyPid announced that it will report its third-quarter 2026 financial results and operational highlights before U.S. markets open on November 11, 2026.6d agoPolyPid introduced PD01B, a Kynatrix-based product candidate for localized, controlled-release antibiotic treatment of diabetic foot infections.7d ago